Status: Not yet recruiting
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD). The main question it aims to answer is: Is PST-611-CT1 safe for participants? Participants will: * Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration
Participants needed: 12
Trial details
Phase: Phase 1Age: 50+Biological sex: AllType: InterventionalSponsor: EyevensysUpdated: Jun 17, 2025Locations: 2
Eligibility criteria
Not listed